Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: A US population-based study

Melanoma Research

Volumn 28, Issue 1, 2018, Pages 56-60

  Uprety, Dipesh ^a   Bista, Amir ^c   Chennamadhavuni, Adithya ^a   Niroula, Abesh ^d   Jafri, Syed Imran Mustafa ^e   Smith, Angela ^b   Arjyal, Lubina ^f  

^a GUNDERSEN HEALTH SYSTEM   (United States)

^b GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^c GUTHRIE RESEARCH INSTITUTE   (United States)

^d Einstein Healthcare Network   (United States)

^e ABINGTON MEMORIAL HOSPITAL   (United States)

^f B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

Author keywords

Immune therapy; metastatic melanoma; population; SEER; survival trend; targeted era

Indexed keywords

IPILIMUMAB; ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; EUROPEAN AMERICAN; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES; ADOLESCENT; CANCER REGISTRY; CANCER STAGING; FOLLOW UP; MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; SECONDARY; SKIN TUMOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SEER PROGRAM; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85042374404     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000394     Document Type: Article

References (26)

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: melanoma of the skin. Available at: http://seer.cancer.gov/statfacts/html/melan.html. [Assessed 30 May 2016].
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
4. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Overview of the SEER Program. Available at: http://seer.cancer.gov/about/overview.html. [Assessed 30 May 30 2016].
5. US Food and Drug Administration Protecting and Promoting Your health. FDA News Release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htm. [Assessed 30 May 2016].
6. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23:488-496.
7. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
8. Harvey VM, Patel H, Sandhu S, Wallington SF, Hinds G. Social determinants of racial and ethnic disparities in cutaneous melanoma outcomes. Cancer Control 2014; 21:343-349.
9. Dawes SM, Tsai S, Gittleman H, Barnholtz-Sloan JS, Bordeaux JS. Racial disparities in melanoma survival. J Am Acad Dermatol 2016; 75:983-991.
10. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006; 166:1907-1914.
11. American Cancer Society California cancer facts and figures 2016. Available at: http://www.ccrcal.org/pdf/Reports/ACS-2016-FF.pdf. [Assessed 1 March 2017].
12. Rouhani P, Hu S, Kirsner RS. Melanoma in hispanic and black Americans. Cancer Control 2008; 15:248-253.
13. Hu S Are we overlooking skin cancer in ethnic minorities? Cutaneous oncology today. Available at: http://bmctoday.net/cutaneousoncologytoday/pdfs/COT1211-Fea-Ethnic.pdf. [Accessed 1 March 2017].
14. Myles ZM, Buchanan N, King JB, Singh S, White A, Wu M, Ajani U. Anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998-2007. Arch Dermatol 2012; 148:797-801.
15. O'Keefe EB, Meltzer JP, Bethea TN. Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010. Front Public Health 2015; 3:51.
16. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002; 94:334-357.
17. Bhatia S, Tykodi SS, Lee SM, Thompson JA. Systemic therapy of metastatic melanoma: on the road to cure. Oncology (Williston Park) 2015; 29:126-135.
18. Blustein J, Weiss LJ. Visits to specialists under Medicare: socioeconomic advantage and access to care. J Health Care Poor Underserved 1998; 9:153-169.
19. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation 1990; 49:374-377.
20. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998; 32:139-145.
21. Wells JS, Strickland OL, Dalton JA, Freeman S. Adherence to intravenous chemotherapy in African American and white women with early-stage breast cancer. Cancer Nurs 2015; 38:89-98.
22. Andic F, Godette K, O'Regan R, Zelnak A, Liu T, Rizzo M, et al. Treatment adherence and outcome in women with inflammatory breast cancer: does race matter? Cancer 2011; 117:5485-5492.
23. Sharma C, Harris L, Haffty BG, Yang Q, Moran MS. Does compliance with radiation therapy differ in African-American patients with early-stage breast cancer? Breast J 2010; 16:193-196.
24. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34:1510-1517.
25. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-1030.
26. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics. Available at: http://seer.cancer.gov/registries/characteristics.html. [Assessed 30 March 2016].